We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
-11.3%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$18.9B
AUM Growth
-$2.79B
(-13%)
Cap. Flow
+$69.4M
Cap. Flow
% of AUM
0.37%
Top 10 Holdings %
Top 10 Hldgs %
29.85%
Holding
751
New
33
Increased
362
Reduced
288
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APA Corp
APA
|
+$112M |
| 2 |
VanEck Gold Miners ETF
GDX
|
+$100M |
| 3 |
RIOM
RIO ALTO MNG LTD NEW COM SHS (CANADA)
RIOM
|
+$100M |
| 4 |
B
Barrick Mining
B
|
+$95.3M |
| 5 |
Fortuna Silver Mines
FSM
|
+$67.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NBIS
Nebius Group N.V.
NBIS
|
+$73.2M |
| 2 |
CNH
CNH Industrial
CNH
|
+$71.5M |
| 3 |
POT
Potash Corp Of Saskatchewan
POT
|
+$55.7M |
| 4 |
Delek US
DK
|
+$54M |
| 5 |
ANDV
Andeavor
ANDV
|
+$52.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 45.04% |
| 2 | Energy | 26.72% |
| 3 | Healthcare | 5.48% |
| 4 | Industrials | 2.98% |
| 5 | Technology | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDVN
151
DELISTED
MEDIVATION, INC.
MDVN
| $18.6M | 0.1% |
376,998
-5,318
| -1% | -$226K |
|
|
PCYC
152
DELISTED
PHARMACYCLICS INC
PCYC
| $18.6M | 0.1% |
157,992
-2,275
| -1% | -$259K |
|
153
Applied Materials
AMAT
$426B
| $18.3M | 0.1% |
846,352
+55,527
| +7% | +$1.23M |
|
154
AbbVie
ABBV
$458B
| $18.2M | 0.1% |
315,780
+36,314
| +13% | +$2.02M |
|
155
Paramount Gold Nevada
PZG
$94.4M
| $18.1M | 0.1% |
20,165,882
+4,241,992
| +27% | +$4.14M |
|
156
Bristol-Myers Squibb
BMY
$127B
| $18.1M | 0.1% |
353,551
+30,820
| +10% | +$1.54M |
|
|
ARMH
157
DELISTED
ARM HOLDINGS PLC ADS
ARMH
| $17.8M | 0.09% |
407,642
+27,513
| +7% | +$1.25M |
|
158
Abbott
ABT
$180B
| $17.5M | 0.09% |
420,968
+42,083
| +11% | +$1.78M |
|
159
Eli Lilly
LLY
$1.07T
| $17.5M | 0.09% |
269,858
+15,017
| +6% | +$951K |
|
160
AstraZeneca
AZN
$263B
| $17.3M | 0.09% |
241,763
+37,567
| +18% | +$2.75M |
|
|
WLB
161
DELISTED
Westmoreland Coal Company
WLB
| $17M | 0.09% |
+453,400
| New | +$18.5M |
|
|
QGENF
162
DELISTED
QIAGEN NV
QGENF
| $16.9M | 0.09% |
743,794
-54,658
| -7% | -$1.24M |
|
163
Incyte
INCY
$23.5B
| $16.8M | 0.09% |
341,514
-4,397
| -1% | -$220K |
|
164
DNOW Inc
DNOW
$2.63B
| $16.6M | 0.09% |
544,524
-1,517
| -0.3% | -$49.7K |
|
|
AGN
165
DELISTED
Allergan Inc
AGN
| $16.2M | 0.09% |
91,038
-1,838
| -2% | -$305K |
|
|
SHPG
166
DELISTED
Shire pic
SHPG
| $16.1M | 0.09% |
62,171
+2,019
| +3% | +$501K |
|
|
TAHO
167
DELISTED
Tahoe Resources Inc
TAHO
| $15.9M | 0.08% |
779,712
+768,900
| +7,112% | +$19.3M |
|
168
Broadcom
AVGO
$1.82T
| $15.8M | 0.08% |
1,815,730
-54,140
| -3% | -$423K |
|
169
Telkom Indonesia
TLK
$14.2B
| $15.6M | 0.08% |
648,836
-106,336
| -14% | -$2.46M |
|
170
Analog Devices
ADI
$181B
| $15.6M | 0.08% |
314,907
+22,145
| +8% | +$1.13M |
|
171
Idexx Laboratories
IDXX
$42.9B
| $15.5M | 0.08% |
262,886
-58,298
| -18% | -$3.69M |
|
172
McKesson
MCK
$98.5B
| $15.1M | 0.08% |
77,754
+68,083
| +704% | +$13.1M |
|
173
AGCO
AGCO
$8.78B
| $14.8M | 0.08% |
324,842
-209,155
| -39% | -$10.4M |
|
174
Teva Pharmaceuticals
TEVA
$35.9B
| $14.7M | 0.08% |
273,078
-18,485
| -6% | -$979K |
|
|
RDC
175
DELISTED
Rowan Companies Plc
RDC
| $14.5M | 0.08% |
574,504
-27,322
| -5% | -$806K |
|
Similar funds
DAM
VanEck Associates's Q3 2014 Portfolio in Review
As of Q3 2014, VanEck Associates held 751 positions worth $18.9B, down 13% from $21.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
VanEck Associates's Q3 2014 filing shows 33 new, 362 increased, 288 reduced and 53 closed positions. Its largest new stake was VanEck Gold Miners ETF: 3,917,124 shares worth $83.7M. The largest sale was Nebius Group N.V., an estimated $73.2M.
By sector, the portfolio is most concentrated in Materials at 45% of assets, down from 45% a quarter earlier, followed by Energy and Healthcare.
- VanEck Associates's largest Q3 2014 buy was VanEck Gold Miners ETF: 3,917,124 shares worth $83.7M.
- VanEck Associates added most to APA Corp in Q3 2014, an estimated $112M increase.
- VanEck Associates's biggest Q3 2014 reduction was Potash Corp Of Saskatchewan, cutting an estimated $55.7M.
- VanEck Associates fully exited Nebius Group N.V. in Q3 2014, selling an estimated $73.2M.
- VanEck Associates's ten largest holdings make up 30% of its $18.9B portfolio in Q3 2014.
- VanEck Associates opened 33 new positions and closed 53 in Q3 2014.
- VanEck Associates's portfolio value fell 13% quarter-over-quarter to $18.9B.
Based on VanEck Associates's 13F filing for Q3 2014, filed 14 Nov 2014.